XML 33 R23.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

9 Months Ended

Sep. 30, 2023

Stock-Based Compensation

Stock-Based Compensation

Note 16. Stock-Based Compensation

Stock Options

During the three and nine months ended September 30, 2023 and 2022, we granted stock options at exercise prices equal to or higher than the quoted market price of our common stock on the grant date. The fair value of each option grant was estimated on the date of grant using Black-Scholes with the following weighted average assumptions:


		September 30,
		2023		2022
Expected life (years)		3.8 - 5.2		3.8 - 5.2
Risk-free interest rate		3.5% - 4.4%		2.1% - 3.7%
Volatility		69.9% - 80.0%		67.5% - 76.8%
Dividend yield		0%		0%

The expected option life assumption is estimated based on the simplified method. Accordingly, the Company has utilized the average of the contractual term of the options and the weighted average vesting period for all options to calculate the expected option term. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected term of our employee stock options. The expected volatility is based on the average of the historical volatility and the implied volatility of our stock commensurate with the expected life of the stock-based award. We do not anticipate paying dividends on the common stock in the foreseeable future.

We recognize stock-based compensation cost on a straight-line basis over the vesting period. Stock-based compensation expense is recognized only for those awards that ultimately vest.

Total stock-based compensation expense related to all of our share-based payment awards is comprised of the following:


		Three Months Ended September 30,						Nine Months Ended September 30,
		2023			2022			2023			2022
Cost of revenues		$	604		$	690		$	1,655		$	1,868
Selling, general and administrative			4,904			4,194			13,973			11,541
Engineering and development			468			482			1,332			1,340
		$	5,976		$	5,366		$	16,960		$	14,749

A summary of stock option activity is as follows:


							Weighted-
				Weighted-			Average
				Average			Remaining		Aggregate
		Number of		Exercise			Contractual		Intrinsic
		Shares		Price/Share			Term (Years)		Value (1)
Outstanding — December 31, 2022		7,340,521		$	15.10		—			—
Granted (weighted-average fair value of $12.03 per share)		394,050			21.03		—			—
Exercised		(407,814)			3.63		—			—
Forfeited		(61,056)			30.11		—			—
Outstanding — September 30, 2023		7,265,701		$	15.93		4.5		$	27,589
Vested (exercisable) — September 30, 2023		6,223,812		$	13.50		4.3		$	27,568
Expected to vest after September 30, 2023 (unexercisable)		1,041,889		$	30.45		6.0		$	21

(1)	Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on September 30, 2023, which was $13.71 per share.

Total intrinsic value of options exercised during the nine months ended September 30, 2023 and 2022 was $6.7 million and $4.9 million, respectively.

As of September 30, 2023, there was unrecognized compensation expense of $17.5 million related to unvested stock options, which we expect to recognize over a weighted average period of 1.9 years.

As of September 30, 2023, the Company had 842,685 shares available for future awards under the Cryoport Inc. 2018 Omnibus Equity Incentive Plan.

Restricted stock units

A summary of our restricted stock unit activity is as follows:


				Weighted Average
		Number of Restricted		Fair Value per
		Stock Units		Share
Outstanding – December 31, 2022		727,984		$	38.32
Granted		628,625			20.00
Share issuance		(221,623)			37.67
Forfeited		(61,146)			31.57
Outstanding – September 30, 2023		1,073,840		$	28.11

For the Three months ended September 30, 2023 and 2022, we recorded stock-based compensation expense on our issued restricted stock units of $2.7 million and $2.1 million, respectively. For the nine months ended September 30, 2023 and 2022, we recorded stock-based compensation expense on our issued restricted stock units of $7.3 million and $5.7 million, respectively. As of September 30, 2023 there was unrecognized compensation expense of $24.8 million related to unvested restricted stock units, which we expect to recognize over a weighted average period of 2.7 years.